Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IBIO 
iBio, Inc. Common Stock (IBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.2
1 Year Target Price $4.2
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.31% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.13M USD | Price to earnings Ratio - | 1Y Target Price 4.2 |
Price to earnings Ratio - | 1Y Target Price 4.2 | ||
Volume (30-day avg) 3 | Beta 0.89 | 52 Weeks Range 0.56 - 6.89 | Updated Date 10/16/2025 |
52 Weeks Range 0.56 - 6.89 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2599% |
Management Effectiveness
Return on Assets (TTM) -44.79% | Return on Equity (TTM) -101.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11316000 | Price to Sales(TTM) 42.81 |
Enterprise Value 11316000 | Price to Sales(TTM) 42.81 | ||
Enterprise Value to Revenue 28.29 | Enterprise Value to EBITDA -1.59 | Shares Outstanding 20254599 | Shares Floating 18608223 |
Shares Outstanding 20254599 | Shares Floating 18608223 | ||
Percent Insiders 3.95 | Percent Institutions 16.54 |
Upturn AI SWOT
iBio, Inc. Common Stock
Company Overview
History and Background
iBio, Inc. was founded in 2008. It focuses on developing and manufacturing biologics. Its evolution has involved strategic shifts toward leveraging its FastPharming System for plant-based protein production.
Core Business Areas
- Biopharmaceutical Development: Focuses on developing therapeutic candidates for various diseases, including fibrosis and cancer. Utilizes iBio's proprietary technologies to create novel biologics.
- Contract Development and Manufacturing Organization (CDMO): Offers contract manufacturing services to other biotech and pharmaceutical companies, leveraging its plant-based expression system for protein production.
Leadership and Structure
iBio is led by a management team with experience in biotechnology and pharmaceuticals. The company has a board of directors overseeing strategic direction and governance.
Top Products and Market Share
Key Offerings
- IBIO-100: A lead candidate in development for the treatment of idiopathic pulmonary fibrosis. No current market share data available as it is still in clinical trials. Competitors include Boehringer Ingelheim and Roche in the broader pulmonary fibrosis treatment market.
- CDMO Services: Contract manufacturing services for various biologics. Revenue fluctuates based on contracts secured. Competition includes Lonza and Catalent in the CDMO space.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high growth and intense competition. CDMO market is also experiencing growth, driven by the increasing complexity of biologics and the need for specialized manufacturing capabilities.
Positioning
iBio differentiates itself through its FastPharming System, which offers rapid and scalable protein production. This positions them as a potential competitor in the CDMO and biopharmaceutical development spaces.
Total Addressable Market (TAM)
The TAM for biopharmaceuticals is in the hundreds of billions of dollars. The CDMO market is also significant, estimated to be over $100 billion. iBio's positioning within these markets is dependent on the success of its pipeline and the growth of its CDMO business.
Upturn SWOT Analysis
Strengths
- Proprietary FastPharming System
- CDMO Capabilities
- Biopharmaceutical Pipeline
Weaknesses
- Limited Financial Resources
- Dependence on CDMO Contracts
- Early-Stage Pipeline Risk
Opportunities
- Expanding CDMO Market
- Partnerships with Larger Pharma Companies
- Positive Clinical Trial Results
Threats
- Competition from Established CDMOs
- Clinical Trial Failures
- Funding Challenges
Competitors and Market Share
Key Competitors
- Lonza (LZAGY)
- Catalent (CTLT)
- Boehringer Ingelheim (N/A - Private)
- Roche (RHHBY)
Competitive Landscape
iBio faces strong competition in both the CDMO and biopharmaceutical spaces. Its FastPharming System provides a potential advantage, but it needs to compete against larger, more established players with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, depending on CDMO contract wins and progress in the biopharmaceutical pipeline.
Future Projections: Future projections are dependent on the success of iBio's pipeline and its ability to secure CDMO contracts. Analyst estimates are available from financial data providers.
Recent Initiatives: Recent initiatives include advancing the IBIO-100 program and expanding CDMO capacity.
Summary
iBio is a biopharmaceutical and CDMO company leveraging its plant-based FastPharming System. The success of its pipeline and CDMO contracts will be key to its future growth. Competition from established players poses a significant challenge, but positive clinical trial results and strategic partnerships could drive future value creation. Financial stability and securing consistent CDMO contracts are crucial for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports (when available)
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data are estimates and may vary. Financial data requires access to real-time financial databases.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iBio, Inc. Common Stock
Exchange NYSE MKT | Headquaters San Diego, CA, United States | ||
IPO Launch date 2008-08-19 | CEO, Chief Scientific Officer & Director Dr. Martin B. Brenner D.V.M., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://ibioinc.com |
Full time employees 20 | Website https://ibioinc.com | ||
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.